Cargando…

Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)

Pharmacogenomics (PGx) is a key subset of precision medicine that relates genomic variation to individual response to pharmacotherapy. We assessed longitudinal trends in US FDA approval of new drugs labeled with PGx information. Drug labels containing PGx information were obtained from Drugs@FDA and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jeeyun A., Ceccarelli, Rachel, Lu, Christine Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000585/ https://www.ncbi.nlm.nih.gov/pubmed/33806453 http://dx.doi.org/10.3390/jpm11030179

Ejemplares similares

Rates of genetic testing in patients prescribed drugs with pharmacogenomic information in FDA-approved labeling
por: Young, John, et al.
Publicado: (2021)

Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information
por: Stanek, Eric J., et al.
Publicado: (2013)

Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing
por: Vivot, Alexandre, et al.
Publicado: (2017)

Characterizing the Strength of Evidence in FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use
por: Chin, Lauren, et al.
Publicado: (2017)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
por: Cicenas, Jonas, et al.
Publicado: (2021)

Participation of Black US Residents in Clinical Trials of 24 Cardiovascular Drugs Granted FDA Approval, 2006-2020
por: Chen, Siliang, et al.
Publicado: (2021)

Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016–2020): A Recapitulation of Chirality
por: Tamatam, Rekha, et al.
Publicado: (2023)

The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2021)

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials
por: Kanapuru, Bindu, et al.
Publicado: (2022)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

FDA eyes pharmacogenomics data.
por: Wakefield, Julie
Publicado: (2004)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
por: Wu, Leihong, et al.
Publicado: (2019)

Use of surrogate outcomes in US FDA drug approvals, 2003–2012: a survey
por: Yu, Tsung, et al.
Publicado: (2015)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
por: Lin, Hui-Heng, et al.
Publicado: (2017)

Findings on In Vitro Transporter-Mediated Drug Interactions and Their Follow-Up Actions for Labeling: Analysis of Drugs Approved by US FDA between 2017 and 2021
por: Lee, Kyeong-Ryoon, et al.
Publicado: (2022)

New Drug and Biologics Approvals in 2019: A Systematic Analysis of Patient Experience Data in FDA Drug Approval Packages and Product Labels
por: Schultz-Knudsen, Katrine, et al.
Publicado: (2020)

Exploration of Potential Ewing Sarcoma Drugs from FDA-Approved Pharmaceuticals through Computational Drug Repositioning, Pharmacogenomics, Molecular Docking, and MD Simulation Studies
por: Hassan, Mubashir, et al.
Publicado: (2022)

Older U.S. Adults With Nocturia Often Cannot Use the Only FDA-Approved Drugs for the Condition
por: Johnson, Theodore, et al.
Publicado: (2020)

Synthesis and clinical application of new drugs approved by FDA in 2022
por: Zhang, Jing-Yi, et al.
Publicado: (2023)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
por: Boyiadzis, Michael M., et al.
Publicado: (2018)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

US FDA Drug Approvals are Persistent and Polycyclic: Insights into Economic Cycles, Innovation Dynamics, and National Policy
por: Daizadeh, Iraj
Publicado: (2021)

US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives
por: Wang, Shawn Shouye, et al.
Publicado: (2021)

Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs
por: Van Norman, Gail A.
Publicado: (2016)

Identification of FDA-approved Drugs Targeting Breast Cancer Stem Cells Along With Biomarkers of Sensitivity
por: Bhat-Nakshatri, Poornima, et al.
Publicado: (2013)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
por: Mahajan, Rajiv
Publicado: (2013)

Possible FDA-approved drugs to treat Ebola virus infection
por: Yuan, Shu
Publicado: (2015)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
por: Tong, Juliana T. W., et al.
Publicado: (2021)

FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rgu3ppr5hdvjqa0k1h06uufmfj